Eyr Medical Danmark ApS

 

Quicksearch
from your own companies




Analyst: XBRLDenmark
 
Loading...

Loading...

Loading...

Loading...

 
Loading...

Bankruptcy Risk 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Bankruptcy risk for industry  0.6% 0.6% 0.6% 0.6% 1.5%  
Bankruptcy risk  29.3% 36.4% 12.3% 18.6% 7.0%  
Credit score (0-100)  2 0 18 7 33  
Credit rating  C C BB B BBB  
Credit limit (kDKK)  -0.0 -0.0 0.0 -0.0 -0.0  

How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12

Net sales  0 0 0 0 0  
Gross profit  -1,515 -1,688 -139 497 1,459  
EBITDA  -2,877 -3,655 -2,262 -1,554 -507  
EBIT  -2,877 -3,655 -2,262 -1,554 -507  
Pre-tax profit (PTP)  -2,887.0 -3,742.0 -2,267.0 -1,558.0 -490.7  
Net earnings  -2,887.0 -3,742.0 -2,267.0 -1,558.0 -490.7  
Pre-tax profit without non-rec. items  -2,887 -3,742 -2,267 -1,558 -491  

 
See the entire income statement

Balance sheet (kDKK) 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12

Tangible assets total  0.0 0.0 0.0 0.0 0.0  
Shareholders equity total  -2,837 -6,578 1,074 -486 -976  
Interest-bearing liabilities  2,735 6,270 0.0 590 1,877  
Balance sheet total (assets)  11.0 194 1,683 996 1,632  

Net Debt  2,735 6,117 -561 395 1,044  
 
See the entire balance sheet

Volume 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12

Net sales  0 0 0 0 0  
Net sales growth  0.0% 0.0% 0.0% 0.0% 0.0%  
Gross profit  -1,515 -1,688 -139 497 1,459  
Gross profit growth  0.0% -11.4% 91.8% 0.0% 193.5%  
Employees  2 2 2 2 2  
Employee growth %  0.0% 0.0% 0.0% 0.0% 0.0%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  11 194 1,683 996 1,632  
Balance sheet change%  0.0% 1,663.6% 767.5% -40.8% 63.8%  
Added value  -2,877.0 -3,655.0 -2,262.0 -1,554.0 -507.2  
Added value %  0.0% 0.0% 0.0% 0.0% 0.0%  
Investments  0 0 0 0 0  

Net sales trend  0.0 0.0 0.0 0.0 0.0  
EBIT trend  -1.0 -2.0 -3.0 -4.0 -5.0  

Profitability 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
EBITDA %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT to gross profit (%)  189.9% 216.5% 1,627.3% -312.7% -34.8%  
Net Earnings %  0.0% 0.0% 0.0% 0.0% 0.0%  
Profit before depreciation and extraordinary items %  0.0% 0.0% 0.0% 0.0% 0.0%  
Pre tax profit less extraordinaries %  0.0% 0.0% 0.0% 0.0% 0.0%  
ROA %  -101.0% -76.0% -53.5% -98.1% -24.0%  
ROI %  -105.2% -81.2% -61.6% -186.7% -39.8%  
ROE %  -26,245.5% -3,650.7% -357.6% -150.5% -37.3%  

Solidity 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Equity ratio %  -92.7% -61.4% 63.8% 10.4% 51.7%  
Relative indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Relative net indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net int. bear. debt to EBITDA, %  -95.1% -167.4% 24.8% -25.4% -205.9%  
Gearing %  -96.4% -95.3% 0.0% -121.4% -192.2%  
Net interest  0 0 0 0 0  
Financing costs %  0.7% 1.9% 0.2% 1.7% 0.0%  

Liquidity 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Quick Ratio  0.1 0.4 2.8 1.1 2.1  
Current Ratio  0.1 0.4 2.8 1.1 2.1  
Cash and cash equivalent  0.0 153.0 561.0 195.0 832.5  

Capital use efficiency 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Trade debtors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Trade creditors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Current assets / Net sales %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net working capital  -139.0 -308.0 1,074.0 104.0 843.7  
Net working capital %  0.0% 0.0% 0.0% 0.0% 0.0%  

Employee efficiency 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Net sales / employee  0 0 0 0 0  
Added value / employee  -1,439 -1,828 -1,131 -777 -254  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  -1,439 -1,828 -1,131 -777 -254  
EBIT / employee  -1,439 -1,828 -1,131 -777 -254  
Net earnings / employee  -1,444 -1,871 -1,134 -779 -245